# Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

> **NCT00306904** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** bevasiranib

## Key facts

- **NCT ID:** NCT00306904
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-09
- **Final completion:** 2007-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2008-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306904, "Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00306904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*